Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has shared an update.
Smith+Nephew announced on August 5, 2025, a share buyback program to return $500 million to shareholders, reflecting strong cash generation and a robust balance sheet from its 12-Point Plan transformation. The program, running from August 5 to December 31, 2025, involves repurchasing shares through J.P. Morgan Securities, with the intent to reduce issued share capital and return surplus capital to shareholders, without affecting growth plans.
The most recent analyst rating on (SNN) stock is a Hold with a $27.27 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats is well-positioned due to strong financial performance and positive earnings call sentiment, highlighting growth and strategic execution. The technical analysis indicates a strong upward trend, although overbought conditions may pose short-term risks. The high P/E ratio suggests potential overvaluation, but the dividend yield adds some appeal for income-focused investors.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue. The company operates in three main business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in 1856 in Hull, UK, Smith+Nephew now operates in around 100 countries and generated annual sales of $5.8 billion in 2024. It is a constituent of the FTSE100.
Average Trading Volume: 856,836
Technical Sentiment Signal: Buy
Current Market Cap: $13.44B
See more insights into SNN stock on TipRanks’ Stock Analysis page.